JPRN-UMIN000017699已完成未知
PERJETA® IV Infusion Drug use surveillance - PERJETA® IV Infusion Drug use surveillance
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 261
研究概览
简要总结
The incidence of adverse drug reactions (ADRs) in the 261 patients in the safety analysis set was 37.54% (98/261 patients), and there were 223 events. The most common ADRs (in 5% or more of patients) were diarrhoea (12.64%, 33/261 patients), neutrophil count decreased (7.66%, 20/261 patients), and malaise (5.74%, 15/261 patients).
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •No criteria
研究者
相似试验
已完成
Unknown
Adverse Drug Reaction Frequency Investigation of TJ-43JPRN-jRCT1080223212Tsumura & Co.3,300
已完成
不适用
General Drug Use Surveillance (All-Patient Surveillance) of POLIVY for Intravenous Infusion 30mg and 140mg (polatuzumab vadotin [genetical recombination]) -Relapsed or refractory diffuse large B-cell lymphomaRelapsed or refractory diffuse large B-cell lymphomaJPRN-UMIN000043840Chugai Pharmaceutical Co. Ltd.1,877
已完成
不适用
Prospective observational study on efficacy and safety of PEGASYS for the treatment of patients with HBeAg positive or HBeAg negative chronic active hepatitis BJPRN-UMIN000008045Chugai Pharmaceutical Co., Ltd.536
已完成
不适用
Actemra, Long-Term Special Drug Use Surveillance in Takayasu arteritis and Giant cell arteritis patientsTakayasu arteritis, Giant cell arteritisJPRN-UMIN000029056Chugai Pharmaceutical Co. Ltd.132
已完成
不适用
Special Drug Use-Results Survey for ACTAIR Sublingual Tablets (Long-term Use)Allergic rhinitis due to house dust mitesJPRN-UMIN000042840Shionogi & Co., Ltd.545